Natera Shares Rise 2.4% After Announcing ctDNA Detection Advance
Natera said incorporating phased and structural variants enables ctDNA detection significantly below 1 part per 10 million, elevating molecular residual disease sensitivity.
Natera (NASDAQ:NTRA) shares rose 2.4% in afternoon trading after the company said that incorporating phased and structural variants enables ctDNA detection at levels significantly below 1 part per 10 million. The advance increases sensitivity for molecular residual disease detection.